Form 4: Galectin CEO Lewis Reports DSU Settlement & Tax Withholding

Galectin Therapeutics CEO Joel Lewis reported the settlement of deferred stock units and shares withheld for tax purposes, executed under a Rule 10b5-1 plan.

Summary

• Joel Lewis, President and CEO of Galectin Therapeutics Inc., reported changes in beneficial ownership.
• The transaction on January 5, 2026, involved the settlement of Deferred Stock Units (DSUs) at a price of $3.88 per share.
• 56,332 shares were withheld from issuance to Mr. Lewis for federal and state withholding taxes on income.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Following the reported transaction, Mr. Lewis directly beneficially owns 776,260 shares of Common Stock.
• He also indirectly owns 2,000 shares as a USTA custodian for a minor child, disclaiming beneficial ownership of these shares.
• The DSUs are part of an employment agreement and Deferred Stock Unit Agreement dated August 31, 2020, amended July 25, 2022, where 80% of his compensation is paid in DSUs.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event involving the settlement of deferred stock units and shares withheld for taxes under a pre-arranged Rule 10b5-1 plan. This is an expected transaction and does not indicate a significant change in company fundamentals or insider sentiment beyond the structured compensation agreement.

Positives

• The transaction is part of a pre-arranged Rule 10b5-1 plan, indicating a structured approach to compensation and share management.
• The settlement of DSUs represents a component of executive compensation, aligning management's interests with shareholders.

Negatives

• 56,332 shares were withheld for taxes, which reduces the number of shares directly held by the CEO from the DSU settlement.

Future Outlook

The filing indicates future DSU settlements, with 50% scheduled for March 1, 2025, and the remaining 50% on January 5, 2026, as per the amended Deferred Stock Unit Agreement.

Industry Context

This Form 4 reflects routine executive compensation practices involving deferred stock units, common across publicly traded companies to align executive incentives with long-term shareholder value. The use of a Rule 10b5-1 plan is a standard practice for insiders to manage stock transactions in compliance with insider trading regulations.

Comparison to Industry Standards

• The use of Deferred Stock Units (DSUs) as a significant component of executive compensation (80% in this case) is a common practice in the biotechnology and pharmaceutical sectors, similar to companies like Biogen or Gilead Sciences, aiming to align executive interests with long-term company performance.
• The implementation of a Rule 10b5-1 plan for stock transactions is an industry-standard best practice for corporate insiders, ensuring compliance with SEC regulations and providing an affirmative defense against insider trading allegations, comparable to practices at major tech or healthcare firms.
• The withholding of shares for tax purposes upon DSU settlement is a standard procedure for equity compensation, mirroring practices observed across all industries for managing tax obligations on vested equity.

Stakeholder Impact

• Shareholders: The transaction reflects a structured executive compensation plan, aligning the CEO's long-term interests with shareholder value through equity ownership.
• Employees: The DSU program is part of the executive compensation structure, which can influence overall compensation philosophy within the company.

Next Steps

• Settlement of the remaining fifty percent of DSUs from the amended agreement on March 1, 2025.
• Settlement of the final fifty percent of DSUs from the amended agreement on January 5, 2026.

Key Dates

Recommendation

This Form 4 details a pre-scheduled executive compensation event (DSU settlement and tax withholding) under a Rule 10b5-1 plan. It is a routine transaction and does not provide new information that would fundamentally alter the investment thesis for Galectin Therapeutics. Therefore, a 'hold' recommendation is appropriate, as the filing does not present a compelling reason to buy or sell based solely on this information.

Keywords

Galectin Therapeutics, GALT, Joel Lewis, Form 4, Insider Transaction, Deferred Stock Units, DSU, Executive Compensation, Rule 10b5-1, Stock Ownership, SEC Filing